
Bioniche Therapeutics is responsible for scientific discovery, pre-clinical research, clinical studies, regulatory submissions, as well as the development and commercialization of human health products derived from proprietary technologies.
Therapeutic Focus
Discovery research at Bioniche focuses primarily on areas of medicine where there is a strong need for safer, more efficacious therapies: specifically in oncology and immunomodulation.
Pre-clinical research and formulation research is conducted in the company's facilities located within the Bioniche Therapeutics Research Centre at the NRC Biotechnology Research Institute in Montreal, Quebec.
Clinical Studies
Bioniche initiated it's Phase III bladder cancer clinical program in November, 2006. The program is being funded and led by Endo Pharmaceuticals Inc. in partnership with Bioniche Life Sciences Inc.
The first Phase III trial involves 105 patients in an open-label protocol showing the efficacy of a formulation of MCC – to be known as UrocidinTM when commercialized - as a therapy in non muscle-invasive bladder cancer that is refractory (unresponsive) to Bacillus Calmette-Guérin (BCG). BCG is a live, attenuated strain of Mycobacterium bovis and is often associated with treatment-limiting side effects including active bacterial infections.
Future plans to further develop UrocidinTM are being defined and will be disclosed by Endo.
For more information about the Company's clinical programs, please contact Bioniche Therapeutics at clinicaltrials@bioniche.com.

Beyond its Canadian licensed cattle vaccine against E. coli O157:H7, trademarked Econiche, Bioniche Food Safety has a pipeline of vaccines in development. These include vaccines against Salmonella, Campylobacter and Listeria, all of which are diseases harboured by animals that can cause human illness.

|